MoonLake Immunotherapeuti... (MLTX)
36.37
-2.70 (-6.91%)
At close: Apr 01, 2025, 3:59 PM
36.35
-0.04%
After-hours: Apr 01, 2025, 04:05 PM EDT
Company Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.
It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation.
The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.
MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics
| Country | CH |
| IPO Date | Oct 20, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Dr. Jorge Santos da Silva |
Contact Details
Address: Dorfstrasse 29 Zug, CH | |
| Website | https://www.moonlaketx.com |
Stock Details
| Ticker Symbol | MLTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001821586 |
| CUSIP Number | 61559X104 |
| ISIN Number | KY61559X1045 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jorge Santos da Silva | Co-Founder, Chief Executive Officer & Director |
| Matthias Bodenstedt | Chief Financial Officer |
| Carla Bretes | Director Investor Relations & Business Development |
| Dr. Kristian Reich | Co-Founder & Chief Scientific Officer |
| Joana Cortez | Senior Director Legal & Compliance |
| Luciana Marques | Director of HR, People & Culture |
| Nicolas Mosimann | General Counsel |
| Nuala Brennan | Chief Clinical Development Officer |
| Oliver Daltrop Ph.D. | Chief Operations Officer |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 03, 2025 | 4 | Filing |
| Mar 03, 2025 | 4 | Filing |
| Mar 03, 2025 | 4 | Filing |
| Feb 26, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 22, 2025 | 4 | Filing |
| Dec 18, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |